Jonathan Allan - 29 Aug 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
GENERAL COUNSEL & CORP SEC
Signature
/s/ Jonathan Allan
Issuer symbol
STOK
Transactions as of
29 Aug 2025
Net transactions value
-$374,109
Form type
4
Filing time
03 Sep 2025, 17:50:21 UTC
Previous filing
20 Aug 2025
Next filing
07 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Allan Jonathan GENERAL COUNSEL & CORP SEC C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan 03 Sep 2025 0001966716

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $6,010 +850 +3.5% $7.07 24,798 29 Aug 2025 Direct
transaction STOK Common Stock Sale $17,000 -850 -3.4% $20.00 23,948 29 Aug 2025 Direct F1
transaction STOK Common Stock Options Exercise $64,690 +9,150 +38% $7.07 33,098 02 Sep 2025 Direct
transaction STOK Common Stock Sale $300,492 -14,922 -45% $20.14 18,176 02 Sep 2025 Direct F1, F2
transaction STOK Common Stock Sale $127,317 -6,345 -35% $20.07 11,831 03 Sep 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Options Exercise $0 -850 -3.3% $0.000000 24,951 29 Aug 2025 Common Stock 850 $7.07 Direct F4
transaction STOK Stock Option (Right to Buy) Options Exercise $0 -9,150 -37% $0.000000 15,801 02 Sep 2025 Common Stock 9,150 $7.07 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive.
F4 The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.